niacinamide has been researched along with Cancer of Esophagus in 12 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results support a rational basis for future clinical studies to assess the therapeutic benefit of Sorafenib in esophageal adenocarcinoma." | 7.74 | Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. ( Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J, 2008) |
| "The morbidity and mortality of esophageal cancer is one of the highest around the world and the principal therapeutic method is radiation." | 5.46 | Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. ( Guo, Z; Kuang, Z; Tan, G; Wei, Q; Wu, X; Yang, G; Yang, S; Zhang, J, 2017) |
| "These results support a rational basis for future clinical studies to assess the therapeutic benefit of Sorafenib in esophageal adenocarcinoma." | 3.74 | Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. ( Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J, 2008) |
| "The morbidity and mortality of esophageal cancer is one of the highest around the world and the principal therapeutic method is radiation." | 1.46 | Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. ( Guo, Z; Kuang, Z; Tan, G; Wei, Q; Wu, X; Yang, G; Yang, S; Zhang, J, 2017) |
| "Lastly, the first effective medical treatment of hepatocellular carcinoma has been presented." | 1.35 | [News in digestive oncology]. ( Di Fiore, F; Michel, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, C | 1 |
| Zhang, H | 1 |
| Zhou, J | 1 |
| Liu, Q | 1 |
| Lu, Q | 1 |
| Zhang, Y | 1 |
| Yu, X | 1 |
| Wang, S | 4 |
| Liu, R | 1 |
| Pu, Y | 1 |
| Yin, L | 1 |
| Wang, N | 3 |
| Pan, D | 3 |
| Wang, X | 7 |
| Su, M | 3 |
| Yan, Q | 3 |
| Sun, G | 3 |
| Liu, H | 1 |
| Shi, G | 1 |
| Jiang, L | 1 |
| Liu, X | 1 |
| Janjigian, YY | 1 |
| Vakiani, E | 1 |
| Ku, GY | 1 |
| Herrera, JM | 1 |
| Tang, LH | 2 |
| Bouvier, N | 1 |
| Viale, A | 1 |
| Socci, ND | 1 |
| Capanu, M | 1 |
| Berger, M | 1 |
| Ilson, DH | 1 |
| Wu, X | 2 |
| Zhang, J | 1 |
| Yang, S | 1 |
| Kuang, Z | 1 |
| Tan, G | 1 |
| Yang, G | 1 |
| Wei, Q | 1 |
| Guo, Z | 1 |
| Delgado, JS | 1 |
| Mustafi, R | 2 |
| Yee, J | 1 |
| Cerda, S | 1 |
| Chumsangsri, A | 2 |
| Dougherty, U | 1 |
| Lichtenstein, L | 1 |
| Fichera, A | 1 |
| Bissonnette, M | 2 |
| Keswani, RN | 1 |
| Delgado, J | 1 |
| Cohen, EE | 1 |
| Shoemaker, RH | 1 |
| Boonstra, JJ | 1 |
| van Marion, R | 1 |
| Beer, DG | 1 |
| Lin, L | 1 |
| Chaves, P | 1 |
| Ribeiro, C | 1 |
| Pereira, AD | 1 |
| Roque, L | 1 |
| Darnton, SJ | 1 |
| Altorki, NK | 1 |
| Schrump, DS | 1 |
| Klimstra, DS | 1 |
| Eshleman, JR | 1 |
| Alvarez, H | 1 |
| Shimada, Y | 1 |
| van Dekken, H | 1 |
| Tilanus, HW | 1 |
| Dinjens, WN | 1 |
| Okines, AF | 1 |
| Reynolds, AR | 1 |
| Cunningham, D | 1 |
| Smavadati, S | 1 |
| Nordfjäll, K | 1 |
| Karlsson, K | 1 |
| Qvarnström, F | 1 |
| Simonsson, M | 1 |
| Bergqvist, M | 1 |
| Gryaznov, S | 1 |
| Ekman, S | 1 |
| Paulsson-Karlsson, Y | 1 |
| Michel, P | 1 |
| Di Fiore, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer[NCT00917462] | Phase 2 | 35 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00917462)
Timeframe: every week while on study
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib | 35 |
(NCT00917462)
Timeframe: anytime prior to enrollment or during protocol therapy
| Intervention | % of tumors with high pERK expression (Number) |
|---|---|
| Sorafenib | 65 |
1 review available for niacinamide and Cancer of Esophagus
| Article | Year |
|---|---|
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
1 trial available for niacinamide and Cancer of Esophagus
| Article | Year |
|---|---|
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm | 2015 |
10 other studies available for niacinamide and Cancer of Esophagus
| Article | Year |
|---|---|
Metabolomic transition trajectory and potential mechanisms of N-nitrosomethylbenzylamine induced esophageal squamous cell carcinoma in rats.
Topics: Animals; Carcinogens; Carcinogens, Environmental; Cell Transformation, Neoplastic; Dimethylnitrosami | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Topics: Case-Control Studies; Esophageal Neoplasms; Humans; NAD; Niacin; Niacinamide; Nicotinamide Phosphori | 2022 |
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Depend | 2014 |
Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcino | 2017 |
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Prolifer | 2008 |
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Topics: Adenocarcinoma; Analysis of Variance; Barrett Esophagus; Benzenesulfonates; Blotting, Western; Cell | 2008 |
Identification of bona fide esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Clinical Trials as Topic | 2010 |
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, | 2010 |
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Topics: Carcinoma, Squamous Cell; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA, Neoplasm | 2012 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Comb | 2008 |